Background: The objective of this study was to investigate prognostic factors and clinical outcome of myxoid/round cell and pleomorphic liposarcoma.

Methods: Three hundred twenty-nine patients with localized myxoid/round cell or pleomorphic liposarcoma who underwent surgery at the Istituto Nazionale per lo Studio e la Cura dei Tumori (Milan, Italy) over 25 years were reviewed. The rates of local recurrence, distant metastases, and survival were studied.

Results: Two hundred fourteen patients presented with primary disease, and 115 patients had locally recurrent tumors. The disease-specific survival rate was 75% at 10 years, and the local recurrence and distant metastases incidence were 25% and 15%, respectively. Presentation with recurrent disease, tumor size (>10 cm), tumor grade (French Federation of Cancer Centers grade II or III vs grade I), and positive surgical margins were independent predictors of death. Tumor site and radiation therapy also played a role, mostly related to their effect on local outcome. Pathologic grade and histologic subtype influenced distant metastases. Extrapulmonary metastases were associated with poorer postmetastatic disease-specific survival.

Conclusions: Myxoid/round cell liposarcomas shared similar prognostic factors with other soft tissue sarcomas and had a relatively good clinical outcome. The presence of >5% of round cell component singled out a group of patients at greater risk of metastases and death but with a broad spectrum of disease aggressiveness. Extrapulmonary metastases were a peculiar pattern of myxoid/round cell liposarcoma that require special consideration for treatment and prognosis.

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.22720DOI Listing

Publication Analysis

Top Keywords

myxoid/round cell
20
cell pleomorphic
12
prognostic factors
12
distant metastases
12
clinical outcome
8
local recurrence
8
recurrence distant
8
extrapulmonary metastases
8
metastases
6
myxoid/round
5

Similar Publications

Novel pharmacotherapies for the treatment of liposarcoma: a comprehensive update.

Expert Opin Pharmacother

December 2024

Department of Hematology/Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA.

Article Synopsis
  • * Recent literature has highlighted novel therapies in development for liposarcomas over the past five years, focusing on targeted therapies and immuno-oncology strategies.
  • * Advances in understanding liposarcoma subtypes have led to promising treatments like CDK4 and MDM2 inhibitors, as well as immune therapies, while the search for effective combination therapies and biomarkers for patient selection is still ongoing.
View Article and Find Full Text PDF
Article Synopsis
  • Liposarcoma is a rare tumor that develops from fat tissue, commonly found in the thigh, but this case involves a tumor in the buttock of a 56-year-old man.
  • The tumor, which had been present for two years, was inflammatory and ulcerated, raising concerns for other diagnoses such as squamous cell carcinoma or skin lymphoma.
  • After confirming the diagnosis of myxoid round-cell liposarcoma, treatment with chemotherapy began but unfortunately led to a rapid deterioration and fatal outcome within weeks.
View Article and Find Full Text PDF

Objective: Recurrence is the leading cause of tumor-related death in retroperitoneal liposarcoma (RPLPS). Variant subtypes of RPLPS determine different recurrence 18F]-fluoro-2-deoxy-D-glucose (18F-FDG) PET/computed tomography (PET/CT). This study analyzed the characteristics of different histologic subtypes of 18F-FDG PET/CT and their associations with recurrence and prognosis.

View Article and Find Full Text PDF

Purpose: Cure models are a useful alternative to Cox proportional hazards models in oncology studies when there is a subpopulation of patients who will not experience the event of interest. Although software is available to fit cure models, there are limited tools to evaluate, report, and visualize model results. This article introduces the R package, an end-to-end pipeline for building mixture cure models, and demonstrates its use in a data set of patients with primary extremity and truncal liposarcoma.

View Article and Find Full Text PDF

Epigenetic determinants of fusion-driven sarcomas: paradigms and challenges.

Front Cell Dev Biol

June 2024

Department of Hematology and Oncology, Cell and Gene Therapy, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.

Article Synopsis
  • Recent advances in understanding fusion-driven sarcomas focus on their epigenetic characteristics, revealing key mechanisms behind sarcomagenesis.
  • Seminal studies in translational genomics have helped us characterize these sarcomas and recognize important factors like chromatin dysregulation and regulatory circuits.
  • Despite specific genetic requirements for oncogenic transformation in fusion partners, the broader epigenetic mechanisms suggest future research may benefit from examining individual cell populations in these rare diseases.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!